MEDICAL ONCOLOGY Zoledronic acid for breast cancer therapy-induced bone loss

被引：10

作者：

Amir, Eitan ^{[1
,2
]}

Ocana, Alberto ^{[1
,2
]}

Seruga, Bostjan ^{[1
,2
]}

Josse, Robert ^{[3
]}

Clemons, Mark ^{[4
]}

机构：

[1] Univ Toronto, Div Med Oncol, Toronto, ON M5G 2M9, Canada

[2] Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada

[3] St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON M5B 1W8, Canada

[4] Ottawa Hosp, Ctr Canc, Div Med Oncol, Ottawa, ON K1H 8L6, Canada

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2010年 / 7卷 / 04期

关键词：

LETROZOLE Z-FAST; POSTMENOPAUSAL WOMEN; FOLLOW-UP;

D O I：

10.1038/nrclinonc.2010.19

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The addition of zoledronic acid to aromatase inhibitors is associated with improved bone mineral density, but not with an effect on clinically-meaningful end points such as fractures. the oncology community should prioritize the design of trials evaluating more relevant end points, such as fragility fracture risk, for treatment-induced bone loss and critically assess the effects of such treatment on breast cancer survival.

引用

页码：187 / 188

页数：2

共 10 条

[1] Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
Brufsky, Adam M.
Bosserman, Linda D.
Caradonna, Richard R.
Haley, Barbara B.
Jones, Michael
Moore, Halle C. F.
Jin, Lixian
Warsi, Ghulam M.
Ericson, Solveig G.
Perez, Edith A.
[J]. CLINICAL BREAST CANCER, 2009, 9 (02) : 77 - 85
[2] Coleman R, 2009, CANCER RES, V69, p733S
[3] Eidtmann H, 2009, CANCER RES, V69, p74S
[4] Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Ellis, Georgiana K.
Bone, Henry G.
Chlebowski, Rowan
Paul, Devchand
Spadafora, Silvana
Smith, Judy
Fan, Michelle
Jun, Susie
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) : 4875 - 4882
[5] Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, Michael
Mlineritsch, Brigitte
Schippinger, Walter
Luschin-Ebengreuth, Gero
Poestlberger, Sabine
Menzel, Christian
Jakesz, Raimund
Seifert, Michael
Hubalek, Michael
Bjelic-Radisic, Vesna
Samonigg, Hellmut
Tausch, Christoph
Eidtmann, Holger
Steger, Guenther
Kwasny, Werner
Dubsky, Peter
Fridrik, Michael
Fitzal, Florian
Stierer, Michael
Rucklinger, Ernst
Greil, Richard
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (07) : 679 - 691
[6] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A
Cuzick, J
Baum, M
Buzdar, A
Dowsett, M
Forbes, JF
Hoctin-Boes, G
Houghton, I
Locker, GY
Tobias, JS
[J]. LANCET, 2005, 365 (9453) : 60 - 62
[7] LOMBARTO A, 2009, P AM SOC CLIN ONCOLO, V213
[8] Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
Seeman, E.
[J]. BONE, 2007, 41 (03) : 308 - 317
[9] Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Williams, Norman
[J]. LANCET ONCOLOGY, 2008, 9 (01) : 45 - 53
[10] WOODWARD EJ, 2009, 9 INT M CANC IND BON

← 1 →